NO20055835L - Cykliske aminderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem - Google Patents

Cykliske aminderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem

Info

Publication number
NO20055835L
NO20055835L NO20055835A NO20055835A NO20055835L NO 20055835 L NO20055835 L NO 20055835L NO 20055835 A NO20055835 A NO 20055835A NO 20055835 A NO20055835 A NO 20055835A NO 20055835 L NO20055835 L NO 20055835L
Authority
NO
Norway
Prior art keywords
processes
preparation
pharmaceutical compositions
compositions containing
cyclic amine
Prior art date
Application number
NO20055835A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055835D0 (no
Inventor
Aldo Feriani
Giuseppe Alvaro
Riccardo Giovannini
Catia Seri
Luca Arista
Francesca Cardullo
Adamo Lucilla D
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20055835D0 publication Critical patent/NO20055835D0/no
Publication of NO20055835L publication Critical patent/NO20055835L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20055835A 2003-05-09 2005-12-08 Cykliske aminderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem NO20055835L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0310724.0A GB0310724D0 (en) 2003-05-09 2003-05-09 Chemical compounds
PCT/EP2004/005005 WO2004099143A1 (en) 2003-05-09 2004-05-07 Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
NO20055835D0 NO20055835D0 (no) 2005-12-08
NO20055835L true NO20055835L (no) 2006-02-07

Family

ID=9957781

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055835A NO20055835L (no) 2003-05-09 2005-12-08 Cykliske aminderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem

Country Status (21)

Country Link
US (2) US20070073061A1 (pt)
EP (1) EP1622871A1 (pt)
JP (1) JP4684221B2 (pt)
KR (1) KR20060009313A (pt)
CN (1) CN100534983C (pt)
AR (1) AR044269A1 (pt)
AU (1) AU2004235967B2 (pt)
BR (1) BRPI0410154A (pt)
CA (1) CA2524894A1 (pt)
EG (1) EG24668A (pt)
GB (1) GB0310724D0 (pt)
IS (1) IS8164A (pt)
MA (1) MA27795A1 (pt)
MX (1) MXPA05012096A (pt)
MY (1) MY140027A (pt)
NO (1) NO20055835L (pt)
NZ (1) NZ543068A (pt)
RU (1) RU2392270C2 (pt)
TW (1) TWI332499B (pt)
WO (1) WO2004099143A1 (pt)
ZA (1) ZA200508339B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412865D0 (en) 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
US7844037B2 (en) 2005-08-08 2010-11-30 Palm, Inc. Method and device for enabling message responses to incoming phone calls
WO2008057856A2 (en) * 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
CN102131779A (zh) * 2008-09-01 2011-07-20 神经研究公司 哌啶-4-乙酰胺衍生物及其作为单胺神经递质再摄取抑制剂的应用
DK2729147T3 (en) 2011-07-04 2017-12-18 Irbm - Science Park S P A NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA
CN106187999A (zh) * 2015-05-04 2016-12-07 复旦大学 取代哌啶类化合物及其制备方法和用途
MX2023011269A (es) 2021-03-23 2024-01-17 Bioage Labs Inc Inhibidores del inflamasoma nlrp3.
CN119053602A (zh) 2022-01-28 2024-11-29 柏奥艾奇实验室公司 Nlrp3炎性体的n-氧化物抑制剂
US12509459B2 (en) 2024-03-26 2025-12-30 BioAge Labs, Inc. Inhibitors of NLRP3 inflammasome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US309720A (en) * 1884-12-23 William p
NL130088C (pt) * 1960-03-14
GB1356118A (en) * 1970-12-16 1974-06-12 Searle & Co 1-3-cyano-3,3-diphenylpropyl-4-phenylpiperidine-4-carboxylic acid derivatives
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
DE19603767A1 (de) * 1996-02-02 1997-08-07 Hoechst Ag Pyrrolidinpropionsäurederivate mit bradykinin-antagonistischer Wirkung
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
AU1415099A (en) * 1997-11-18 1999-06-07 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
JP4280073B2 (ja) * 2001-04-12 2009-06-17 ファーマコペイア ドラッグ ディスカバリー, インコーポレイテッド Mchアンタゴニストとして使用されるアリールピペリジンおよびビアリールピペリジン
HUP0402404A3 (en) * 2001-11-26 2011-05-30 Schering Corp Use of new piperidine-based mch antagonists for producing pharmaceutical compositions suitable for the treatment of obesity and cns disorders
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
WO2004005256A2 (en) * 2002-07-03 2004-01-15 Glaxo Group Limited Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors

Also Published As

Publication number Publication date
EG24668A (en) 2010-04-11
RU2005138315A (ru) 2007-06-20
IS8164A (is) 2005-12-01
CA2524894A1 (en) 2004-11-18
AU2004235967A1 (en) 2004-11-18
BRPI0410154A (pt) 2006-05-16
NZ543068A (en) 2009-07-31
US20070073061A1 (en) 2007-03-29
MA27795A1 (fr) 2006-03-01
KR20060009313A (ko) 2006-01-31
MY140027A (en) 2009-11-30
CN100534983C (zh) 2009-09-02
TW200510309A (en) 2005-03-16
AU2004235967B2 (en) 2008-10-23
NO20055835D0 (no) 2005-12-08
JP2006525975A (ja) 2006-11-16
EP1622871A1 (en) 2006-02-08
US20090192194A1 (en) 2009-07-30
CN1819995A (zh) 2006-08-16
GB0310724D0 (en) 2003-06-11
ZA200508339B (en) 2006-10-25
JP4684221B2 (ja) 2011-05-18
RU2392270C2 (ru) 2010-06-20
AR044269A1 (es) 2005-09-07
WO2004099143A1 (en) 2004-11-18
MXPA05012096A (es) 2006-02-08
TWI332499B (en) 2010-11-01

Similar Documents

Publication Publication Date Title
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
NO20052683D0 (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20042155L (no) N-adamantylmetylderivater og mellomprodukter som farmasoytiske sammensetninger og fremgangsmater til deres fremstilling
NO20054006D0 (no) Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer
DK1670458T3 (da) 1-Amino-2-oxy-substituerede tetrahydronaphthalenderivater, fremgangsmåder til fremstilling deraf og deres anvendelse som antiphlogistika
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
DK1322158T3 (da) Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
NO20023643D0 (no) Forbindelser som har antitumoraktivitet, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholderdem
DK1558612T3 (da) Imidazopyridinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK2083007T3 (da) Tiotropiumsalte, fremgangsmåder til deres fremstilling og lægemiddelformuleringer indeholdende disse
NO20055835L (no) Cykliske aminderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
IS7424A (is) Oxasólídínónafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær
NO20043188L (no) Nye heterocykliske oksimforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20031219D0 (no) Nye forbindelser avledet fra kinazolin, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem
DK2067779T3 (da) Tiotropiumsalte, fremgangsmåde til deres fremstilling og lægemiddelformuleringer indeholdende disse
NO20031643L (no) Nye aminotriazolonforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem
DK1707564T3 (da) Indanyl-piperazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK1742927T3 (da) Butanonsyrederivater, fremgangsmåder til fremstilling deraf, farmaceutiske præparater omfattende dem, og farmaceutiske applikationer deraf
NO20055167D0 (no) Nye benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20034614L (no) Nye [3,4-a:3,4-c]karbazolforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20041313L (no) Nye isokinolinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20035215L (no) Tricykliske dihydrokinolinforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20052414L (no) Nye pyrrolidin- og tiazolidinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20043910L (no) Nye aminosyreforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20042422L (no) Nye benzotiazin- og benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem